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Iron repletion is associated with reduction in
platelet counts in non-dialysis chronic kidney
disease patients independent of erythropoiesisstimulating agent use: a retrospective cohort study
Lenar Yessayan1*, Jerry Yee1, Gary Zasuwa1, Stan Frinak1 and Anatole Besarab2

Abstract
Background: Iron deficiency is common in non-dialysis chronic kidney disease (ND-CKD) patients and, on occasion,
requires parenteral iron therapy. We investigated the effect of intravenous iron repletion on platelet counts in ND-CKD
patients with and without concomitant darbepoetin administration.
Methods: We conducted a retrospective analysis of ND-CKD patients with iron deficiency anemia treated with low
molecular weight iron dextran (LMWID) between 2005 and 2009 at our CKD clinic. The primary end-point was change
in platelet count 60 days post infusion of LMWID in those with and without concomitant darbepoetin administration.
Secondary end-points were the correlations between changes in platelet count and iron indices.
Results: A total of 108 patients met inclusion and exclusion criteria. The decrease in platelet counts in response to iron
repletion was statistically significant (305.72 ± 108.86 vs 255.58 ± 78.97, P = < .0001). The decrease in platelet count was
independent of concomitant darbepoetin use. Bivariate regression analysis between baseline platelet count and
transferrin saturation by iron (TSAT) showed a negative association (βTSAT = −5.82, P = .0007) and moderate correlation
(R = 0.32). Following iron treatment, the within individual changes in platelet count in 60 days were not related to
changes in TSAT (βΔTSAT = −0.41, P = .399) and demonstrated a poor correlation (R = 0.10).
Conclusions: Parenteral iron treatment by LMWID is associated with reduction in platelet counts in iron deficient
anemic ND-CKD patients. However, ESA use in the majority of patients prior to intravenous iron administration could
have altered platelet production through bone marrow competition.
Keywords: Thrombocytosis, Platelet count, Iron deficiency anemia, Erythropoietin, Intravenous iron dextran

Background
Thrombocytosis may be the result of a clonal disorder
or secondary to a reactive process such as acute or
chronic inflammation, hyposplenism, malignancy, or
iron deficiency. The mechanism of thrombocytosis in
iron deficiency related anemia is not completely understood. Thrombocytopoiesis is orchestrated by a complex
interplay between growth factors and cytokines. Thrombopoietin is the primary growth factor and regulator of
megakaryopoiesis [1]; however, several other cytokines
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such as interleukin (IL)-1, IL-3, IL-6, IL-11 and tumor necrosis factor are involved in this process [2-7]. Erythropoietin shares some structural features with thrombopoietin
and may exhibit synergistic effect on platelet production
[8,9]. However, the small degree of functional overlap is
not mediated by cross-reactivity at the level of mpl receptor expressed on the surface of megakaryocytes [10].
Treatment with exogenous erythropoietin may increase
platelet count [11]. It may be that the mechanism of synergy is mediated through the expression of erythropoietin
receptors on megakaryocyte progenitors. It has also been
suggested that the mechanism by which erythropoiesis
stimulating agents (ESA) increase platelet count may be
through the induction of a state of functional iron
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deficiency [12]. Some have suggested that reactive thrombocytosis, induced by ESA or the resulting iron depletion,
may have contributed to the higher-than-expected rates of
cerebrovascular accidents and thrombotic events reported
in clinical trials of ESA in chronic kidney disease (CKD)
patients. At the Henry Ford Hospital Chronic Kidney Disease Clinic, low molecular weight iron dextran (LMWID)
in conjunction with ESA is used for non-dialysis chronic
kidney disease (ND-CKD) anemia management using a
computerized algorithm for dosing. We undertook the
present study to evaluate the temporal effect of intravenous iron administration on platelet counts in iron deficient
ND-CKD patients and determine if the effect is dependent
on concurrent ESA administration.

Methods
This single-center retrospective cohort study was approved by our hospital’s institutional review board (IRB
project number 6650; Henry Ford Health Systems Institutional Review Board). We performed a chart review of
all ND-CKD patients enrolled in our CKD clinic’s computerized anemia management program (CAMP) [13]
who received iron dextran (INFeD, Watson Pharmaceuticals, Parsippany, NJ) between August 25, 2005 and
March 6, 2009. CAMP is designed to treat anemia of
CKD using darbepoetin alpha (DA) and iron treatment
algorithms. Data on patients’ hematologic variables are
stored in the CAMP database irrespective of whether
they received the recommended dose of iron/ESAs.
After manual data input, the iron dosing algorithm recommends no iron, oral iron, or 1 g of LMWID over 1.5–
2 hours based on hemoglobin, TSAT, and ferritin levels
obtained within 30 days of iron infusion. At all times,
iron “sufficiency” is to be achieved/maintained with oral
or parenteral ID per the algorithm [14]. The dosing of
LMWID (500 or 1000 mg) during this study period was
at the discretion of the treating physician. DA doses
were determined monthly, based on three separate protocols for first, second, and maintenance DA doses with
the goal to achieve and maintain Hb in the range of
10.0–12.0 g/dL [13].
Eligible patients were adults (≥18 years) with CKD
who received a single dose of LMWID during a 2-month
period and who were not on maintenance ESA therapy
prior to LMWID administration. Exclusion criteria were
any of the following: documented surgery, gastrointestinal bleeding, hospitalization during the evaluation
period; lack of follow-up on second evaluation (within
37 days from baseline) or on third evaluation (within
37 days from second evaluation); administration of ESAs
within 30 days of LMWID infusion. Of the 131 subjects
identified, 108 ND-CKD patients met eligibility criteria.
All of these study subjects received either a 500 mg or
1000 mg infusion by peripheral vein over 1.5–2.0 hours.
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No patient received a LMWID test dose and none were
premedicated with diphenhydramine. We previously reported that LMWID is safe and effective in the treatment of iron deficiency in ND-CKD [14]. However,
because fatal anaphylactic reactions have been reported
after administration of LMWID injection, resuscitation
techniques and treatment of anaphylactic and anaphylactoid shock are readily available in our CKD clinic.
Baseline platelet counts, hemoglobin and iron indices
were obtained within 1 week prior to LMWID administration, at 30 and 60 days post LMWID administration.
The primary end-point was the change in platelet count
at ~ 60 days from iron administration (baseline) in those
with and without concomitant DA administration. Secondary end-points were changes in iron indices at ~ 30
and 60 days from baseline and the correlation between
changes in iron indices and platelet count following
LMWID administration. To detect a reduction in platelets of 25 000/mm3 with a two-sided 5% significance
level and a power of 80%, a sample size of at least 60 patients was necessary to account for an anticipated 20%
exclusion, either because of lack of follow-up or presence of intercurrent events. To include at least this
number of patients, a 48-month inclusion period was
considered.
Statistical analysis was performed using SAS software
version 9.3 (SAS Institute, Inc., Cary, NC). We used Student’s paired t-test to measure intra individual changes
between time points for platelets, ferritin, and TSAT.
Pearson correlation coefficients were used to evaluate
the relationship between platelet count and iron indices
at baseline as well as between changes in platelet counts
and iron indices 60 days post-administration. Categorical
variables are presented as frequencies and percentages.
Continuous variables are presented using mean ± standard deviation. For all analyses, a P value < .05 was considered significant.

Results
Table 1 shows demographics and baseline laboratory
values of 108 patients receiving LMWID infusions stratified by concomitant DA use. All CKD stages were represented (Table 1). Stages 3 and 4 CKD were the most
common and CKD stage 1 was the least common. There
were 65 (60%) 1000 mg LMWID infusions and 43 (40%)
500 mg LMWID infusions administered. Of the 108 subjects, 94 received monthly DA injections either on the
day of iron infusion or 30 days prior to iron infusion or
both; and 14 patients did not receive any DA within
30 days prior to iron infusion or during the evaluation
period. Figure 1 shows the mean monthly doses of DA
over time in the DA group.
Following administration of LMWID, hemoglobin, ferritin, and iron saturation increased significantly at 30
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Table 1 Baseline characteristics of patients receiving intravenous iron dextran stratified by darbepoetin exposure
Darbepoetin

No darbepoetin

N = 94

N = 14

P value

69.51 ± 15.90

67.79 ± 17.26

0.7088 (T)

45/47/1/1

13/1/0/0

0.0181 (F)

58/36

11/3

0.2202 (C)

304.53 ± 106.97

313.71 ± 124.87

0.7699 (T)

9.98 ± 1.22

11.44 ± 1.43

<0.0001 (T)

Demographics
Age
Race, n (White, Black, Asian, Hispanic)
Gender, n (Female/Male)
Laboratory
Baseline platelets (1000/mm3)
Hemoglobin (g/dL)
Transferrin saturation (%)

13.07 ± 6.26

12.71 ± 4.41

0.8361 (T)

Ferritin (ng/mL)

43.07 ± 36.05

33.50 ± 23.10

0.3379 (T)

1 (1%)

0 (0%)

0.4453 (C)

CKD stage
Stage 1
Stage 2

6 (6%)

0 (0%)

Stage 3

40 (43%)

9 (64%)

Stage 4

38 (40%)

5 (36%)

Stage 5

9 (10%)

0 (0%)

Demographics are reported as frequencies except for age which is reported as mean ± standard deviation. Laboratory parameters are reported as mean ± standard
deviation. Chronic kidney disease (CKD) stages are reported as frequencies with percentages in parenthesis. (T) = Two-sided T-Test, (C) = Chi-Square Test, (F) = Fisher
Exact Test.

and 60 days. Concomitantly, at 30 and 60 days, a statistically significant decrease occurred in platelet counts in
response to iron repletion (Table 2). When platelet response was stratified according to DA use (Table 3),
there was a statistically significant decrease in platelet
counts from baseline at 30 days in both groups (DA
group 304.53 ± 106.97 vs 274.26 ± 136.27, P = 0.008; No
DA group 313.71 ± 124.87 vs 279.00 ± 130.08, P = 0.0021).
At 60 days, a statistically significant decrease in platelet
counts of approximately 50 000/mm3 was observed in
both groups in response to iron repletion. The change in
platelet count was similar when stratified according to DA

Figure 1 Darbepoetin alfa (mcg) ± SD utilization over duration
of study in the group that received Darbepoetin alfa. Pre-baseline
indicates within 30 days of iron infusion. Baseline indicates the day
of iron infusion.

use (−50.12 ± 63.36 for DA group vs −50.29 ± 74.64 for
No DA group, P = .9928). Irrespective of iron dose, a decrease in platelet count was observed (Table 4). The
change in platelet count 60 days post-LMWID was similar
when platelet response was stratified according to dose of
LMWID administered (−50.33 ± 61.40 for 500 mg vs
−50.02 ± 67.02 for 1000 mg; P = .9806).
Bivariate regression analysis between the baseline
platelet count and TSAT revealed a negative association
between the 2 variables. The estimated baseline platelet
count increased by ≈ 5820 for each 1% decrease in TSAT
(βTSAT = −5.82, P = .0007). The correlation coefficient R
between baseline platelet and TSAT was 0.32. No association was found between baseline platelet count and
ferritin (βferritin = −0.32, P = .2838), and the correlation
coefficient R was not significant (R = 0.10, P = .2838).
The linear correlation between changes in platelet
counts and iron indices in response to LMWID at
60 days was also investigated. The change in platelet
count in ~ 60 days was neither related to changes in iron
saturation (βΔTSAT = −0.41, P = .3991) nor ferritin (βferritin =
0.07, P = .1458), as displayed in Figures 2 and 3, respectively. Both predictor variables exhibited a weak and statistically non-significant correlation with platelet change
(R = −0.09, R = −0.15, respectively). To test the robustness
of this result, we repeated this analysis after the exclusion
of patients who did not have any improvement in their
TSAT by 60 days from baseline. The poor correlation persisted even after the exclusion of these patients (R =
−0.07934).
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Table 2 Parameter comparison at baseline, 30 days and 60 days post-LMWID administration
Parameter
Platelet count (1000/mm3)

Pre-infusion

30 days

Mean ± SD

Mean ± SD

p-value

305.72 ± 108.86

274.71 ± 135.04

0.0012

60 days

p-value

Mean ± SD
255.58 ± 78.97

<0.0001

Hemoglobin (g/dL)

10.17 ± 1.34

11.29 ± 1.66

<0.0001

11.38 ± 1.70

<0.0001

Ferritin (ng/mL)

41.83 ± 34.71

203.29 ± 168.75

<0.0001

154.13 ± 156.39

<0.0001

Transferrin saturation (%)

13.03 ± 6.03

23.62 ± 12.60

<.00001

25.06 ± 13.30

<0.0001

Discussion
Secondary thrombocytosis is associated with many
conditions, including acute or chronic inflammation,
hyposplenism, and iron deficiency. Although generally
regarded as a benign condition, secondary thrombocytosis has been identified as an independent risk factor for
thromboembolic events in patients with cancer [15-17].
Similarly, iron deficiency with and without thrombocytosis has been linked to venous thrombosis and stroke
[18-20]. Thus, it is biologically plausible that reactive
thrombocytosis, induced by ESA or the resulting iron
depletion, may have contributed to the higher-thanexpected rates of cerebrovascular accidents and thrombotic events reported in clinical trials of ESA in CKD
patients (e.g., the cardiovascular risk reduction by early
anemia treatment with epoetin beta [CREATE] trial, a
trial of end-stage renal disease patients that compared
the effects of normal as compared with low hematocrit
values in patients with cardiac disease who were receiving hemodialysis and epoetin, and a trial to reduce
cardiovascular events with Aranesp therapy [TREAT])
[21-23] as postulated by Streja et al. [24]. In their retrospective analysis of more than 40 000 hemodialysis patients, Streja et al. [24] noted relative thrombocytosis in
15% (defined as platelet count > 300 000 ± 109 000/L),
and this was associated with a 30% greater weekly dose

of ESA, lower TSAT, and lower serum ferritin concentration. This pattern is reflective of functional iron deficiency at the bone marrow level.
Megakaryopoiesis is regulated by various cytokines
[1-7]. The pathophysiologic mechanism behind reactive
thrombocytosis in iron deficiency is complex and incompletely understood. Akan et al. [25] demonstrated that
the correction of iron deficiency anemia and resolution
of thrombocytosis do not alter cytokine levels that are
typically elevated in reactive thrombocytosis (IL-6, IL-11,
and thrombopoietin). Although the levels of endogenous
erythropoietin significantly decreased during correction
of iron deficiency, the same response was observed in
those with and without thrombocytosis, indicating that
erythropoietin is not the principal regulator of thrombocytosis [25].
Studies of intravenous iron undertaken in predialysis
chronic renal failure that evaluated hematologic parameters have not reported the effect on platelet counts
[26-30]. This observational study evaluated the effect of
intravenous LMWID on platelet counts in iron deficient
anemic ND-CKD patients with and without concomitant
ESA use. We also evaluated the relationship between
baseline platelets and iron storage parameters, as well as
the relationship between changes in iron storage parameters and platelets. In response to iron administration, a

Table 3 Parameter comparison pre-LMWID and post-LMWID infusion stratified by darbepoetin administration
Darbepoetin (N = 94)
Parameter
Platelet count (1000/mm3)
Hemoglobin (g/dL)

Pre-infusion

30 days

p-value

60 days
254.41 ± 80.16

<0.0001

Mean ± SD

Mean ± SD

304.53 ± 106.97

274.26 ± 136.27

0.008

p-value

Mean ± SD

9.98 ± 1.22

11.12 ± 1.61

<0.0001

11.22 ± 1.70

<0.0001

Ferritin (ng/mL)

43.07 ± 36.05

208.06 ± 171.79

<0.0001

150.58 ± 151.79

<0.0001

Transferrin saturation (%)

13.07 ± 6.26

24.32 ± 12.83

<0.0001

25.83 ± 13.55

<0.0001

p-value

60 days

p-value

No Darbepoetin (N = 14)
Parameter

Pre-infusion

30 days

Mean ± SD

Mean ± SD

313.71 ± 124.87

279.00 ± 130.08

0.0021

263.43 ± 72.68

0.0256

Hemoglobin (g/dL)

11.44 ± 1.43

12.66 ± 1.51

0.0049

12.46 ± 1.30

0.0053

Ferritin (ng/mL)

33.50 ± 23.10

135.00 ± 103.01

0.0276

192.25 ± 208.21

0.0620

Transferrin saturation (%)

12.71 ± 4.41

16.00 ± 6.07

0.1047

16.75 ± 5.92

0.0683

Platelet count (1000/mm3)

LMWID = low molecular weight iron dextran.

Mean ± SD
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Table 4 Parameter comparison pre-LMWID and 60 days post-LMWID infusion stratified by iron dextran dose
Iron dextran 1000 mg

Iron dextran 500 mg

N = 65
Pre-infusion
Platelet count (1000/mm3)

Post-infusion

N = 43
P value

Pre-infusion
Mean ± SD

Mean ± SD

278.79 ± 86.27

228.47 ± 54.87

<0.0001

Mean ± SD

Mean ± SD

323.54 ± 118.82

273.52 ± 87.34

<0.0001

Post-infusion

P value

Hemoglobin (g/dL)

10.24 ± 1.41

11.60 ± 1.63

<0.0001

10.07 ± 1.23

11.04 ± 1.78

0.0001

Ferritin (ng/mL)

46.22 ± 38.31

174.60 ± 158.25

<0.0001

35.21 ± 27.54

122.59 ± 150.15

0.0005

Transferrin saturation (%)

13.60 ± 6.43

24.95 ± 12.12

<0.0001

12.16 ± 5.34

25.24 ± 15.07

<0.0001

LMWID = low molecular weight iron dextran.

statistically significant decrease occurred in platelet
counts of about 50 000/mm3, suggesting a mechanistic
link between iron deficiency and platelet counts in patients with ND-CKD. The effect of iron repletion on
platelet count was observed in those who did and did
not receive ESAs suggesting that the effect of iron repletion on platelet counts is independent of ESA use.
In our study the correlation between baseline platelet
and TSAT was weak to moderate and negative in direction (R = −0.31); this is consistent with previously reported negative associations between baseline iron stores
and platelet counts. One recent study showed only a
very weak correlation between baseline platelet count
and iron stores and no reduction in platelet count after
intravenous iron dextran [31]. However, contrary to our
study, the after dose values were measured between 10–
120 days. Interestingly, when we investigated the relationship of within individual change in platelet count in
response to a change in TSAT, we only found a weak
and insignificant correlation. This would imply that our
current parameters for iron deficiency, TSAT and ferritin,

Figure 2 Regression fit plot of within individual changes in
platelets versus changes in transferrin saturation.

may be insensitive and imprecise measures of iron availability to the bone marrow. To date, the only definitive
way in clinical practice to prove the presence of iron deficiency in CKD is to evaluate the erythropoietic response
to parenteral iron administration. However, both reticulocyte hemoglobin content (CHr) and the percentage of hypochromic red cells may be better indicators of iron
deficiency (CHr area under the curve [AUC] = 0.935 for a
cutoff of 29.8 pg, sensitivity 90.7%, specificity 83.1%; percent hypochromic cells AUC = 0.925, cutoff 3.5%, sensitivity 87.3%, and specificity 88.0%) [32] than the traditional
measurements of TSAT and ferritin, which have sensitivities and specificities < 80%.
This study has several limitations. Its retrospective nature makes it subject to selection and information bias.
Selection bias was constrained by including all patients
within the prespecified dates; however, some patients
were excluded because of a lack of follow-up or intercurrent events. Moreover, given the retrospective design,
patients with undocumented intercurrent events in our
records such as gastrointestinal bleed, infection and

Figure 3 Regression fit plot of within individual changes in
platelets versus changes in ferritin.
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surgery may have been included in the study and caused
bias in the point estimate of the correlation. However,
an uncertainty analysis that was performed with the exclusion of those who did not have any improvement in
their TSAT yielded similar results. Additionally, by design, we could not fully control information bias; however, any observer bias was limited by data abstraction
from the anemia management database. This study suggests that iron replacement is associated with reduction in
platelet counts in iron deficient ND-CKD patients independent of ESA use and extends the observation of
Eschbach’s study [33], where it was noted that almost half
of their 333 study patients developed iron deficiency with
platelet counts increasing following erythropoietin administration to anemic end-stage renal disease patients. Aggressive iron therapy reversed this increase in platelets.
Another limitation was the absence of data regarding
inflammatory markers, such as C-reactive protein and
erythrocyte sedimentation rate, and for this reason, we
could not adjust for the effect of inflammatory status, if
any, on platelet count change. Furthermore, the majority
of our patients did not have thrombocytosis (median =
284 000, interquartile range = 236–359). The decrease in
platelet count following LMWID could only be extrapolated to patients within the specified platelet count range
in our cohort. Whether iron administration could induce
a more pronounced change in platelet count in iron deficient patients with thrombocytosis warrants further
investigation.

Conclusion
In conclusion, our study implies that intravenous iron is
associated with reduction in platelet counts independent
of ESA use. However, without a control group not receiving IV iron, causation cannot be confirmed. Adequately powered studies are needed to establish an
association between thrombocytosis, iron deficiency and
thromboembolic events in ND CKD patients.
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